DoW Ovarian Cancer, Clinical Trial Award
Can you apply?
This grant is for researchers conducting clinical trials on ovarian cancer treatments. Eligible applicants include academic institutions, hospitals, research organizations, and individual researchers with relevant expertise. The program supports U.S.-based organizations and institutions. Funding supports clinical trial design, patient recruitment, data collection, and analysis of ovarian cancer interventions.
Program description
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.
Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Who can apply
Eligible applicants
Demographic focus
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Federal Application for Grants and Cooperative Agreements)
- Project Narrative/Research Plan
- Budget and Budget Justification
- Biographical Sketches (key personnel)
- Institutional Support Letter
- IRB Approval or IRB Submission Plan
- Letters of Commitment from Partner Sites
Program contact
- 👤 Christopher Meinberg Grantor
- 📧 help@ebrap.org
- 📞 3016192657
Funding track record
Recent awards under CFDA 12.420 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$2,265,729,366
-
$800,631,761
-
$74,531,880
-
$67,205,571
-
$53,718,832
-
$34,191,124
-
$24,907,742
-
$21,394,379
-
$19,100,256
-
$19,002,641
Top States by Funding
- MD 10 awards $3,150.1M
- NC 11 awards $132.3M
- FL 8 awards $99.8M
- CA 11 awards $99.3M
- MA 7 awards $75.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 12.420). How funding has trended year over year.
| 2024 | $1,483,968,520 | |
| 2025 | $1,201,153,417 |
FAQ
Who can apply for this grant?
Academic medical centers, hospitals, research institutes, and individual researchers with institutional affiliation can apply. Individual practitioners and small clinics may apply if they have appropriate institutional infrastructure for clinical trials.
What is the application deadline?
The deadline is October 1, 2026. Applications open May 4, 2026. Plan to submit several weeks before the deadline.
What types of clinical trial research are supported?
The program funds Phase I, II, and III clinical trials for ovarian cancer treatments. Studies examining new therapies, drug combinations, or novel treatment approaches are prioritized.
How competitive is this funding?
DoD medical research grants are moderately to highly competitive. Strong preliminary data, experienced research teams, and clear clinical impact improve competitiveness.
What is the typical funding range?
Awards typically range from $500,000 to $3 million over the project period. Actual amounts vary based on project scope and agency priorities.
💡 Tips for applicants
- Demonstrate preliminary data from prior studies or pilot work supporting your trial design. Reviewers want evidence of feasibility.
- Clearly describe recruitment strategy with realistic enrollment projections. Many trials fail due to poor patient recruitment planning.
- Include detailed timeline with major milestones and decision points. Clinical trials need clear progress markers.
- Highlight institutional support: IRB approval pathway, patient access, clinical infrastructure. Show your organization can execute this trial.
- Connect your work to DoD priorities in cancer research and military-relevant outcomes where possible. Funding is competitive, so alignment matters.
⚠️ Common mistakes
Weak or missing preliminary data undermines credibility. Many applications lack realistic patient recruitment and retention plans. Insufficient detail on trial protocol, endpoints, or statistical analysis causes rejection.
Similar grants
- OPEN National HIV Clinical Training for Residents Program — Health Resources and Services Administration
- OPEN NIAMS Clinical Trial Implementation Cooperative Agreement — National Institutes of Health
- OPEN Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases — National Institutes of Health
- OPEN Nutrition Security for People with HIV: Implementation Technical Assistance Provider — Health Resources and Services Administration
- OPEN Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed) — National Institutes of Health